Keros Therapeutics

KROS

Market cap $595M

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Keros Therapeutics (KROS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administration. A rebound in mergers and acquisitions (M&A) has also increased investor confidence in the industry.

Here we discuss five value stocks that are cheap in terms of price-to-book, price-to-sales and PEG. These are StoneCo, GM, EnerSys, Deutsche Bank and Keros.

Does Keros Therapeutics, Inc. (KROS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Keros Therapeutics, Inc. (KROS) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?